AWM Investment Company Inc. Has $13.61 Million Stock Holdings in argenex SE $ARGX

Key Points

• AWM Investment Company Inc. has reduced its stake in argenex SE by 8.0%, now holding 23,000 shares valued at approximately $13.6 million.
• Several institutional investors have increased their positions in argenex, with Dimensional Fund Advisors LP raising holdings by 21.7% and Northern Trust Corp by 42.7% in the last quarter.
• Analysts have shown confidence in argenex, with the average price target set at $772.84 and multiple upgrades from "hold" to "buy" ratings.

AWM Investment Company Inc. reduced its holdings in argenex SE (NASDAQ:ARGX - Free Report) by 8.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 23,000 shares of the company's stock after selling 2,000 shares during the quarter. argenex comprises 1.9% of AWM Investment Company Inc.'s portfolio, making the stock its 19th biggest holding. AWM Investment Company Inc.'s holdings in argenex were worth $13,613,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Rakuten Securities Inc. raised its stake in shares of argenex by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after purchasing an additional 22 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in argenex during the 4th quarter worth about $38,000. WPG Advisers LLC bought a new stake in shares of argenex in the 1st quarter valued at about $37,000. Golden State Wealth Management LLC bought a new stake in shares of argenex in the 1st quarter valued at about $44,000. Finally, Brooklyn Investment Group grew its holdings in shares of argenex by 102.7% in the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company's stock valued at $44,000 after buying an additional 38 shares during the period. 60.32% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ARGX shares. Bank of America boosted their price target on shares of argenex from $880.00 to $887.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Piper Sandler increased their target price on argenex from $750.00 to $820.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 26th. JMP Securities set a $699.00 target price on argenex in a research note on Wednesday, May 14th. Robert W. Baird raised argenex from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a research note on Tuesday, May 13th. Finally, Wells Fargo & Company increased their target price on argenex from $741.00 to $756.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating and twenty-one have assigned a Buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $772.84.

argenex Stock Up 1.4%

Shares of NASDAQ ARGX traded up $10.18 during trading hours on Monday, hitting $760.96. The company had a trading volume of 152,630 shares, compared to its average volume of 375,938. The stock has a market capitalization of $46.57 billion, a P/E ratio of 39.00, a price-to-earnings-growth ratio of 0.80 and a beta of 0.41. argenex SE has a 1-year low of $510.05 and a 1-year high of $763.37. The firm's 50 day moving average is $627.89 and its 200-day moving average is $602.06.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. The company had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. On average, sell-side analysts predict that argenex SE will post 3.13 earnings per share for the current year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.